MedPath

Effect of adding HD-tDCS to regular treatment on social cognition in schizophrenia and its correlation with blood levels of oxytoci

Phase 3
Conditions
Health Condition 1: F202- Catatonic schizophreniaHealth Condition 2: F201- Disorganized schizophreniaHealth Condition 3: F208- Other schizophreniaHealth Condition 4: F200- Paranoid schizophreniaHealth Condition 5: F205- Residual schizophreniaHealth Condition 6: F209- Schizophrenia, unspecifiedHealth Condition 7: F203- Undifferentiated schizophrenia
Registration Number
CTRI/2023/08/056169
Lead Sponsor
Central Institute of Psychiatry
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Diagnosis of Schizophrenia using Diagnostic Criteria for Research (DCR) of International Classification of Disease-11th edition (ICD-11, World Health Organization,1993)

2.Males aged between 18- 60 years

3.Illness duration of equal to or more than 2 years.

4.Patients giving written informed consent.

5.Right handed.

6.The Positive and Negative Syndrome Scale for Schizophrenia (PANSS), positive score less than 11.

7.Calgary Depression Scale for Schizophrenia (CDSS) score less than7.

Exclusion Criteria

1.Co-morbid neurological or any other medical or psychiatric disorder

2.History of substance abuse(except nicotine and caffeine)

3.History of epilepsy, significant head injury or any other neurosurgical procedures

4.Patients who have received electroconvulsive therapy or neuromodulation techniques in the past one month

5.Having any metallic implants in body

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Impact on social cognition after application of HD-tDCSTimepoint: Social cognition at baseline & 04 weeks after HDtDCS treatment
Secondary Outcome Measures
NameTimeMethod
Change in serum oxytocin from baseline to post treatmentTimepoint: Serum oxytocin levels at baseline & 04 weeks after HDtDCS treatment
© Copyright 2025. All Rights Reserved by MedPath